Value assessment of early innovation serves to assess the commercial potential of a medical technology given its expected characteristics (e.g. efficacy, safety, mode of administration). At this stage, there is often no final product but instead initial (promising) results from early stage studies (e.g. preclinical or phase 1).
The questions that the developers of the technology might ask are “What is the market potential of the technology in terms of price and number of patients?”, “Which patient group should be targeted to generate the greatest expected return for the company?”, “Which market access activities should be performed and when?” One way of answering these questions is to conduct value assessment research involving early decision-making models and data generation plans.